160 likes | 327 Views
Richard Carter Head of Industry Sponsorship Department of Health London. Presentation. Co-operation of public authorities and industry: why is it necessary to work together? The UK experience. The DH role in co-ordinating policy Our aim and why we do this How we go about it
E N D
Richard CarterHead of Industry SponsorshipDepartment of HealthLondon
Presentation Co-operation of public authorities and industry: why is it necessary to work together? The UK experience
The DH role in co-ordinating policy Our aim and why we do this How we go about it - Pharmaceuticals - Medical technology Characteristics of the relationship Outline of the presentation
Our aim: The Government's strategy is to build on the UK’s reputation as being a leader in life sciences, and to work with both industries to improve the environment for them to continue to innovate.
Why do we do this? • Importance of these industries to the economy of the UK • Vital role of each sector in supporting Government’s health goals and policies • Importance of innovation to health care reform
Pharmaceutical Industry Invests over £3bn annually in R&D in the UK £12bn of medicines exported from the UK annually 68,000 directly employed by the pharmaceutical industry 16 of the worlds top-selling 75 medicines discovered in the UK Medical technology Annual output is in the region of £4bn including £2.2bn to the NHS Exports are about £2bn 55,000 directly employed by the medical technology industry Pharmaceutical & Medical Technology sectors in the UK
How do we go about it? – Pharmaceuticals • History of the relationship is long • Since 1999 more systematic architecture of engagement • 1999-2001 PICTF • 2001-present MISG • MISG - industry side membership global, government side ministers and top officials • Meets twice a year • Joint consideration of strategic issues of common interest, e.g. science education
Close Dialogue & Partnership with Industry-MISG & Long Term Leadership Strategy Ministerial Industry Strategy Group (MISG) MISG has overseen the development of the Long Term Leadership Strategy for Medicines (LTLS) which is designed to: • secure the provision of safe and effective medicines for patients; • maintain and strengthen the UK pharmaceutical industry within Europe; • and to advance healthcare innovation in the UK.
Close Dialogue & Partnership with Industry- MISG - Long Term Leadership Strategy Three workstreams have reported on their conclusions: • Partnership Working Group: Dealing with the industry’s relationships with the NHS in England and with uptake of cost effective medicines • European Working Group: Improving the business and technology environment for the pharmaceutical industry in Europe • Regulatory Working Group: Developing the regulatory environment in the UK and Europe so as better to serve needs of all stakeholders
How do we go about it – Medical Technology • Shorter history of joint engagement • Healthcare Industries Task Force (HITF) a year long joint Initiative was set up in 2003 • Beginning of an important dialogue between Government and the sector • Implementation of its key outputs from 2004 • New strategic group – Ministerial Medical Technology Strategy Group – set up to take forward recommendations • Will meet twice a year • Will consider strategic issues of common interest, e.g. small business support in this sector, innovation
Key outputs of HITF • Integration of technology evaluation into procurement - Centre for Evidence-based Purchasing (CEP) • Establishment of a National Innovation Centre (NIC) • Strengthened R&D environment for medical technologies • Streamlined procurement process • Continuing shared strategic agenda and architecture within which to pursue it
Medical Technology - Published Reports 2004 and 2007 Further details are available on: www.advisorybodies.doh.gov.uk/hitf
Characteristics of the relationships • Well established long term engagement • Very senior representation from both sides on the two joint government/industry groups • Genuine interest on both sides in holding constructive dialogue at strategic level • Openness and transparency • Ability to disagree without rupturing the connection • Strong horizontal working across relevant government departments
The UK Governmentpharmaceutical & medical technologyIndustry linkages: a schematic overview • Pharmaceuticals FCO/UKTI Inward investment DIUS Skills • Medical Technology DFID Access to medicines NHSIII/NIC HO Animal rights legislation DBERR Science base DH Co-ordination & policy/ Purchaser/NHS NHS PASA Procurement, device evaluation HMT Tax incentives/ Science strategy MHRA EU medicines/device legislation NICE Appraisals of New technologies UKCRC Translational Clinical research OSCHR Health research
KeyMessages • Government committed to a strong relationship with industry • Both parties to the relationship benefit • Working in partnership wherever possible has enabled us to achieve many shared goals